BHVN (Biohaven Ltd.)
Insider Trading Activity
Every open-market purchase and sale reported by BHVN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-19 | Kishan Mehta | Director | G | — | — |
| 2026-03-09 | JOHN W CHILDS | Director | Buy | — | — |
| 2026-03-03 | Kimberly Gentile | SVP, Clinical Operations | A | — | — |
| 2026-03-03 | Matthew Buten | Chief Financial Officer | A | — | — |
| 2026-03-03 | George C. Clark | VP, Chief Accounting Officer | A | — | — |
| 2026-03-03 | Vlad Coric | Chief Executive Officer | A | — | — |
| 2026-03-03 | Bruce Car | Chief Scientific Officer | A | — | — |
| 2026-01-07 | Kimberly Gentile | SVP, Clinical Operations | MIXED | — | — |
| 2026-01-07 | Vlad Coric | Chief Executive Officer | MIXED | — | — |
| 2026-01-07 | George C. Clark | VP, Chief Accounting Officer | MIXED | — | — |
| 2026-01-07 | Matthew Buten | Chief Financial Officer | MIXED | — | — |
| 2026-01-07 | Bruce Car | Chief Scientific Officer | MIXED | — | — |
| 2025-11-18 | George C. Clark | VP, Chief Accounting Officer | Buy | — | — |
| 2025-11-17 | JOHN W CHILDS | Director | Buy | — | — |
| 2025-11-17 | Vlad Coric | Chief Executive Officer | Buy | — | — |
| 2025-11-17 | Gregory Bailey | Director | Buy | — | — |
| 2025-05-07 | Irina Antonijevic | Director | A | — | — |
| 2025-05-07 | JULIA P GREGORY | Director | A | — | — |
| 2025-05-07 | Gregory Bailey | Director | A | — | — |
| 2025-05-07 | ROBERT J HUGIN | Director | A | — | — |
| 2025-05-07 | Kishan Mehta | Director | A | — | — |
| 2025-05-07 | JOHN W CHILDS | Director | A | — | — |
| 2025-05-07 | Michael Thomas Heffernan | Director | A | — | — |
| 2025-03-05 | JOHN W CHILDS | Director | Buy | — | — |
| 2025-03-05 | JOHN W CHILDS | Director | Buy | — | — |
| 2025-01-07 | Kimberly Gentile | SVP, Clinical Operations | MIXED | — | — |
| 2025-01-07 | Matthew Buten | Chief Financial Officer | MIXED | — | — |
| 2025-01-07 | Bruce Car | Chief Scientific Officer | MIXED | — | — |
| 2025-01-07 | George C. Clark | VP, Chief Accounting Officer | MIXED | — | — |
| 2025-01-07 | Vlad Coric | Chief Executive Officer | MIXED | — | — |
| 2024-12-31 | JOHN W CHILDS | Director | Buy | — | — |
| 2024-10-03 | Vlad Coric | Chief Executive Officer | Buy | — | — |
| 2024-10-03 | JOHN W CHILDS | Director | Buy | — | — |
| 2024-09-25 | Gregory Bailey | Director | Buy | — | — |
| 2024-07-19 | JOHN W CHILDS | Director | Buy | — | — |
| 2024-06-20 | Bruce Car | Chief Scientific Officer | Buy | — | — |
| 2024-05-31 | JOHN W CHILDS | Director | Buy | — | — |
| 2024-05-15 | Gregory Bailey | Director | Buy | — | — |
| 2024-05-14 | JOHN W CHILDS | Director | Buy | — | — |
| 2024-05-02 | Gregory Bailey | Director | A | — | — |
| 2024-05-02 | Irina Antonijevic | Director | A | — | — |
| 2024-05-02 | ROBERT J HUGIN | Director | A | — | — |
| 2024-05-02 | JULIA P GREGORY | Director | A | — | — |
| 2024-05-02 | JOHN W CHILDS | Director | A | — | — |
| 2024-05-02 | Michael Thomas Heffernan | Director | A | — | — |
| 2024-05-02 | Kishan Mehta | Director | A | — | — |
| 2024-04-25 | Gregory Bailey | Director | Buy | — | — |
| 2024-04-23 | Gregory Bailey | Director | Buy | — | — |
| 2024-04-23 | Vlad Coric | Chief Executive Officer | Buy | — | — |
| 2024-04-23 | JOHN W CHILDS | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 8,015,222 | — |
| — | Chief Executive Officer | 3,006,673 | — |
| — | Director | 2,020,071 | — |
| — | Chief Financial Officer | 198,246 | — |
| — | SVP, Clinical Operations | 101,513 | — |
| — | VP, Chief Accounting Officer | 86,978 | — |
| — | Chief Scientific Officer | 40,096 | — |
| — | Director | 25,665 | — |
| — | Director | 22,662 | — |
| — | Director | 15,178 | — |
| — | Director | 13,535 | — |
| — | Director | 12,959 | — |
| — | Chief Commercial Officer | 1,614 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BHVN quote page; the site-wide leaderboard is on the insider transactions hub.